Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systolic Hypertension Clear all
Recruiting Not applicable Interventional

Inspiratory Muscle Strength Training in Chronic Kidney Disease

NCT04911491
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension, Aging, Blood Pressure
Interventions
IMST, Sham Training
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional

Minding GOALS: An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control

NCT02694432
View directory record Official record
Conditions
Hypertension
Interventions
GOALS, Minding GOALS
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 22, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

NCT04040959
View directory record Official record
Conditions
Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
Interventions
Nicotinamide riboside
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
35 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

NCT00698646
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan + HCTZ, Valsartan, HCTZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jul 22, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional

Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function

NCT07109739
View directory record Official record
Conditions
Systolic Hypertension, Brachial Artery Flow-mediated Dilation
Interventions
POWERbreathe K5
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 5:54 AM EDT
Terminated Not applicable Interventional Results available

Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration

NCT03303391
View directory record Official record
Conditions
ESRD, Extracellular Fluid Alteration, Hypertension
Interventions
Intradialytic Blood Pressure Slope Based Ultrafiltration
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Jul 22, 2026, 5:54 AM EDT
Completed No phase listed Observational

Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study

NCT01475747
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
View directory record Official record
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Jul 22, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional

Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)

NCT00089713
View directory record Official record
Conditions
Hypertension
Interventions
alagebrium chloride (ALT-711)
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2010 · Synced Jul 22, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

NCT01065051
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jul 22, 2026, 5:54 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Accuracy of Non-Invasive Blood Pressure Measurement in Adults

NCT01183741
View directory record Official record
Conditions
Hypertension, Hypotension
Interventions
Not listed
Lead sponsor
Sotera Wireless, Inc.
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smartphone App-guided Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure

NCT06229873
View directory record Official record
Conditions
Blood Pressure, Vascular Function, Adherence, Treatment
Interventions
App-Based Inspiratory Muscle Strength Training, Clinic-Based Inspiratory Muscle Strength Training
Device
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 5:54 AM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

NCT00772577
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide, Ramipril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

NCT00853957
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Jul 22, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional

Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure

NCT06962488
View directory record Official record
Conditions
Hypertension, Atherosclerotic Cardiovascular Disease
Interventions
Regular Care, SBP PRS Dissemination
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 5:54 AM EDT
Not listed Not applicable Interventional

Evaluating Infrasonic Hemodynography

NCT04636892
View directory record Official record
Conditions
Aortic Stenosis, Mitral Regurgitation, Pulmonary Hypertension, Heart Failure, Systolic, Cardiovascular Diseases, Coronary Artery Disease
Interventions
MindMics earbud
Other
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 22, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Interventions
Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
Drug · Other
Lead sponsor
Rong Zhang
Other
Eligibility
60 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure

NCT00939640
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (SRD)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 22, 2026, 5:54 AM EDT
Withdrawn No phase listed Observational

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

NCT02560116
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Jul 22, 2026, 5:54 AM EDT